Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration

NCT02222207 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02222207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02222207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2014
Completion date
June 30, 2015
Enrollment
52 (actual)
Sites
149

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration